A BiAb, cevostamab (BFCR4350A), targeting FcRH5 and CD3, was constructed and showed significant in vitro and in vivo anti-MM activity, as well as T cell activation/proliferation in a preclinical study [120]. Here, FCRL5 is linked to Miyoshi myopathy.